FRIDAY, Jan. 27 (HealthDay News) -- Bydureon (exenatide extended
release), Amylin Pharmaceuticals' long-acting version of the
diabetes drug Byetta, has been approved by the U.S. Food and Drug
Administration.
The once-weekly injection will include a label warning that the
drug caused certain thyroid tumors in rats, the
Dow Jones news service reported. It's not known whether the
drug causes such tumors in people, the label warning says. But the
drug shouldn't be used by people with a family history of medullary
thyroid carcinoma (a form of cancer), the warning continues.
Twice in 2010, the FDA declined approval of Bydureon, requesting
additional studies and clinical information,
Dow Jones reported.
Bydureon is a "glucagon-like peptide-1 (GLP-1) receptor," a
class of medications that helps the body produce more insulin,
which helps regulate blood sugar.
Amylin is based in San Diego, Calif.
More information
For more about
type 2 diabetes, visit MedlinePlus.